Ananda Developments

Directors

Shareholders

Announcements

Publications

Broker Coverage

Company and Advisors

Corporate Governance

Home

Updates

Investment Opportunity

Ubuntu

Pharmacokinetic (PK) studies are crucial for understanding how a drug behaves within the body. These studies involve a series of methodical steps designed to provide comprehensive data on the drug’s absorption, distribution, metabolism, and excretion. This blog outlines the key activities and processes that take place during a PK study.

Following our announcement that we will be running a Phase 1 PK study in Australia, we thought this topic would be a good one to cover to everyone with some more detail behind these studies. 

Before a PK study begins, a detailed study protocol is developed. This protocol outlines the study’s objectives, the drug administration schedule, the sampling times, and the methods for data analysis. The study design must consider factors such as the expected therapeutic dose range, inclusion and exclusion criteria for participants, and what should be measured and when.

Participants for PK studies are selected based on specific criteria to ensure consistency and reliability of the data. These criteria can include age, gender, health status, and sometimes genetic factors that might influence drug metabolism.

One critical factor that MRX has ensured for its PK study is a 50/50 sex split between males and females.

The investigational drug is administered to participants according to the study protocol. The route of administration (oral, intravenous, etc.) and the dosage is carefully controlled to ensure accurate measurement of pharmacokinetic parameters.

Blood samples are collected at predetermined intervals after drug administration. These samples are used to measure the concentration of the drug and its metabolites over time. Depending on the study, other biological samples such as urine, saliva, or tissue biopsies may also be collected.

The collected samples are analysed using techniques such as liquid chromatography-mass spectrometry (LC-MS) to determine the drug concentrations. This data is then used to create concentration-time profiles, which are essential for calculating key pharmacokinetic parameters.

Cmax:     The maximum concentration of the drug in the bloodstream.

Tmax:     The time it takes to reach the maximum concentration.

AUC      (Area Under the Curve): Represents the total drug exposure over time.

Half-Life:     The time it takes for the drug’s concentration to reduce by half.

Clearance:     The rate at which the drug is eliminated from the body.

The data from PK studies provide insights into how the drug is absorbed, distributed, metabolised, and excreted. These results help determine the appropriate dosing regimen, identify any potential safety concerns, and understand the drug’s overall behaviour in the body.

Throughout the PK study, strict adherence to Good Clinical Practice (GCP) and regulatory guidelines is maintained. This ensures the integrity of the data and the safety of the participants.

Pharmacokinetic studies are a systematic and essential part of drug development. They involve careful planning, precise execution, and detailed analysis to understand how a drug moves through the body. The insights gained from these studies are critical for developing safe and effective dosing regimens and advancing new therapies through the clinical trial process.